<DOC>
	<DOC>NCT00438789</DOC>
	<brief_summary>The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.</brief_summary>
	<brief_title>The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>PNH; At least 18 years old Avoid conception; and Willing and able to give written informed consent Active bacterial infection Participation in any other drug trial Pregnant breast feeding, or intending to conceive Not vaccinated against N meningitidis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>